| Sofosbuvir and ribavirin in HCV genotypes 2 and 3 S Zeuzem, GM Dusheiko, R Salupere, A Mangia, R Flisiak, RH Hyland, ... New England Journal of Medicine 370 (21), 1993-2001, 2014 | 1041 | 2014 |
| Expansion of HIV-specific T follicular helper cells in chronic HIV infection M Lindqvist, J Van Lunzen, DZ Soghoian, BD Kuhl, S Ranasinghe, ... The Journal of clinical investigation 122 (9), 3271-3280, 2012 | 512 | 2012 |
| Frequent neurocognitive deficits after recovery from mild COVID-19 MS Woo, J Malsy, J Pöttgen, S Seddiq Zai, F Ufer, A Hadjilaou, ... Brain communications 2 (2), fcaa205, 2020 | 444 | 2020 |
| Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naive patients T Kuntzen, J Timm, A Berical, N Lennon, AM Berlin, SK Young, B Lee, ... Hepatology 48 (6), 1769-1778, 2008 | 434 | 2008 |
| CD8 epitope escape and reversion in acute HCV infection J Timm, GM Lauer, DG Kavanagh, I Sheridan, AY Kim, M Lucas, T Pillay, ... The Journal of experimental medicine 200 (12), 1593-1604, 2004 | 388 | 2004 |
| Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients–FINITE study T Berg, KG Simon, S Mauss, E Schott, R Heyne, DM Klass, C Eisenbach, ... Journal of hepatology 67 (5), 918-924, 2017 | 287 | 2017 |
| Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence J Schulze zur Wiesch, D Ciuffreda, L Lewis-Ximenez, V Kasprowicz, ... Journal of Experimental Medicine 209 (1), 61-75, 2012 | 279 | 2012 |
| Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes J Schulze zur Wiesch, GM Lauer, CL Day, AY Kim, K Ouchi, JE Duncan, ... The Journal of Immunology 175 (6), 3603, 2005 | 241 | 2005 |
| Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+ T Regulatory Cells Correlates with … J Schulze zur Wiesch, A Thomssen, P Hartjen, I Tóth, C Lehmann, ... Journal of virology 85 (3), 1287-1297, 2011 | 239 | 2011 |
| High Level of PD-1 Expression on Hepatitis C Virus (HCV)-Specific CD8+ and CD4+ T Cells during Acute HCV Infection, Irrespective of Clinical Outcome V Kasprowicz, J Schulze zur Wiesch, T Kuntzen, BE Nolan, S Longworth, ... Journal of virology 82 (6), 3154-3160, 2008 | 235 | 2008 |
| Spontaneous control of HCV is associated with expression of HLA-B* 57 and preservation of targeted epitopes AY Kim, T Kuntzen, J Timm, BE Nolan, MA Baca, LL Reyor, AC Berical, ... Gastroenterology 140 (2), 686-696. e1, 2011 | 180 | 2011 |
| Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals J Dietz, S Susser, J Vermehren, KH Peiffer, G Grammatikos, A Berger, ... Gastroenterology 154 (4), 976-988. e4, 2018 | 179 | 2018 |
| Clonal expansion and activation of tissue-resident memory-like TH17 cells expressing GM-CSF in the lungs of patients with severe COVID-19 Y Zhao, C Kilian, JE Turner, L Bosurgi, K Roedl, P Bartsch, AC Gnirck, ... Science Immunology 6 (56), eabf6692, 2021 | 167 | 2021 |
| The magnitude and breadth of hepatitis C virus–specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1 AY Kim, GM Lauer, K Ouchi, MM Addo, M Lucas, JS Wiesch, J Timm, ... Blood 105 (3), 1170-1178, 2005 | 156 | 2005 |
| Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV … H Wedemeyer, P Bogomolov, A Blank, L Allweiss, M Dandri-Petersen, ... J Hepatol 68 (1), S3, 2018 | 155 | 2018 |
| SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients DF Ruether, GM Schaub, PM Duengelhoef, F Haag, TT Brehm, A Fathi, ... Clinical Gastroenterology and Hepatology 20 (1), 162-172. e9, 2022 | 145 | 2022 |
| Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm … K Deterding, CD Spinner, E Schott, TM Welzel, G Gerken, H Klinker, ... The Lancet infectious diseases 17 (2), 215-222, 2017 | 143 | 2017 |
| Full-Breadth Analysis of CD8+ T-Cell Responses in Acute Hepatitis C Virus Infection and Early Therapy GM Lauer, M Lucas, J Timm, K Ouchi, AY Kim, CL Day, JS Zur Wiesch, ... Journal of virology 79 (20), 12979-12988, 2005 | 136 | 2005 |
| CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X M Karimova, N Beschorner, W Dammermann, J Chemnitz, D Indenbirken, ... Scientific reports 5 (1), 13734, 2015 | 131 | 2015 |
| A phase 3, randomized trial of bulevirtide in chronic hepatitis D H Wedemeyer, S Aleman, MR Brunetto, A Blank, P Andreone, ... New England Journal of Medicine 389 (1), 22-32, 2023 | 130 | 2023 |